Inosine 5 -monophosphate dehydrogenase (IMPDH) is the ratelimiting enzyme in the de novo biosynthesis of guanine nucleotides. In addition to the catalytic domain, IMPDH contains a subdomain of unknown function composed of two cystathione β-synthase domains. Our results, using three different assays, show that IMPDHs from Tritrichomonas foetus, Escherichia coli, and both human isoforms bind single-stranded nucleic acids with nanomolar affinity via the subdomain. Approx. 100 nucleotides are bound per IMPDH tetramer. Deletion of the subdomain decreases affinity 10-fold and decreases site size to 60 nucleotides, whereas substitution of conserved Arg/Lys residues in the subdomain with Glu decreases affinity by 20-fold. IMPDH is found in the nucleus of human cells, as might be expected for a nucleic-acid-binding protein. Lastly, immunoprecipitation experiments show that IMPDH binds both RNA and DNA in vivo. These experiments indicate that IMPDH has a previously unappreciated role in replication, transcription or translation that is mediated by the subdomain.
INTRODUCTION
Inosine 5 -monophosphate dehydrogenase (IMPDH) catalyses the rate-limiting and first committed step of guanine nucleotide metabolism, the oxidation of IMP (inosine 5 -monophosphate) to XMP (xanthosine 5 -monophosphate) with the reduction of NAD. IMPDH controls the size of the guanine nucleotide pool, which in turn controls many physiological processes, including replication, transcription, signalling and glycosylation [1] . Inhibitors of IMPDH are antiproliferative, which makes the enzyme an important drug target for immunosuppressive, antiviral and cancer chemotherapy [2] [3] [4] [5] .
Intriguingly, IMPDH may have a more complex role in cellular regulation than generally appreciated. Virtually all IMPDHs contain a subdomain of unknown function in addition to the catalytic domain [6] . The catalytic domain is an α-β barrel of approx. 400 residues. The approx. 100 residue subdomain consists of two cystathione β-synthase (CBS) domains and protrudes from the opposite end of the barrel from the active site. The subdomain can be deleted with no effect on enzymic activity [7, 8] . The presence of the subdomain indicates that IMPDH has another, as yet undefined, role in metabolism in addition to the production of XMP. Autosomal dominant retinitis pigmentosa has recently been attributed to mutations in the subdomain of human IMPDH type I [9, 10] , although the mechanism of this pathology is not understood.
We have serendipitously discovered that IMPDH binds to singlestranded nucleic acid with nanomolar affinity. Moreover, this nucleic-acid-binding activity involves the subdomain, and is the Abbreviations used: DTT, dithiothreitol; CBS, cystathione β-synthase; ChIP, chromatin immunoprecipitation; dT 60 etc., 60-mer (etc.) thymidine homo-oligonucleotide; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; IMP, inosine 5 -monophosphate; IMPDH, inosine 5 -monophosphate dehydrogenase; K d , dissociation constant; NLS, nuclear localization signal; R212E etc., substitution of Arg 212 with Glu 212 etc.; SSB, single-stranded DNA-binding protein; ssDNA, single-stranded DNA; Tf SD IMPDH, Tritrichomonas foetus IMPDH with the subdomain deleted; XMP, xanthosine 5 -monophosphate. 1 Present address: Hygiene-Institut, Abteilung Parasitologie, Universitat Heidelberg, Im Neuenheimer Feld 324, 69120 Heidelberg, Germany. 2 Present address: Archemix Corp., 1 Hampshire St., Cambridge, MA 02139, U.S.A. 3 To whom correspondence should be addressed (e-mail hedstrom@brandeis.edu).
first and only function assigned to this region. Further, we show that IMPDH is located in the nucleus of human cells and binds both RNA and DNA in vivo. While this work was in progress, another laboratory found that Saccharomyces cerevisiae IMPDH binds to telomeric sequences [11] . These observations suggest that IMPDH has a previously unappreciated role in RNA and/or DNA metabolism.
EXPERIMENTAL Materials
All oligonucleotides were obtained from Qiagen Operon (Alameda, CA, U.S.A.). Heparin, poly(dT), poly(dU), poly(dA), poly(dC) and protein A-Sepharose were obtained from Sigma.
[ Site-directed mutagenesis was performed on the plasmid pTf1 [12] using the QuikChange mutagenesis kit from Stratagene. The following primers and their exact complements were used to create the R212E/R217E and K230E/R231E double mutants respectively: 5 -CGTTATATCGTTTTCGAAAAAGATTATGA-CGAATCGCAAGTCTGTC-3 and 5 -CGAACTCGTCGATT-CGCAAGAAGAATATTTGGTCGGAGCAGG-3 . The nicked vector products were transformed into Escherichia coli ultracompetent XL-1 Blue cells. To ensure that no undesired mutations were introduced, the resulting IMPDH cDNAs were sequenced using the ABI PRISM 377 DNA Sequencer.
Protein purification
Human type II, T. foetus and E. coli IMPDHs, and T. foetus IMPDH with the subdomain removed (Tf SD IMPDH), were purified as described previously [8, [12] [13] [14] . The human IMPDH type I was expressed in E. coli using the pKK223-3 vector (Pharmacia, Piscataway, NJ, U.S.A.). The protein was purified using Cibacron Blue-Sepaharose and IMP-Sepharose as described previously for human IMPDH type II [13] . The two double mutants of T. foetus IMPDH (R212E/R217E and K230E/R231E) were also expressed in E. coli and purified according to the same protocol as T. foetus IMPDH [12] . A His-tagged version of the subdomain of human type I IMPDH was expressed in E. coli, independently of the catalytic domain. The sequence (singleletter symbols) of this expressed construct is MRGSHHHHHHG-MASMTGGQQMGRDPEPEFQANEVRKVKNFEQGFITDPV-VLSSHTVGDVLEAKMRHGFSGIPITETGTMGSKLVGIVTS-RDIDFLAEKDHTTLLSEVMTPRIELVVAPAGVTLKEANEI-LQRSKKGKLPIVNDCDEVAIIARTDLKKNRNSKLDPAAN-KARKEAELAAATAQQ. This protein was purified using an immobilized-metal affinity chromatography column with an imidazole elution followed by an 80 % (w/v) ammonium sulphate precipitation. All protein preparations were > 95 % homogeneous as judged by SDS/PAGE.
ssDNA (single-stranded DNA) filter-binding studies
All experiments were performed in 50 mM Tris/HCl, pH 8.0, 1 mM DTT (dithiothreitol) and 50 mM KCl, unless otherwise indicated. Pools of ssDNA were assayed for binding to IMPDH from various sources using dot-blot filter binding. The sequence of ssDNA in the pool was GGGAATGGATCCACATCTACGAA-TTC-N 30 -TTCACTGCAGACTTGACGAAGCTT, where N 30 denotes a random sequence 30 bases long. 5 -32 P-labelled ssDNA (2 nM) and protein were mixed in 10 mM Tris/HCl, pH 7.5, 50 mM KCl and 1 mM DTT for 10 min at 25
• C. The mixture was filtered on a vacuum manifold (Schleicher and Schuell, Keene, NH, U.S.A.) equipped with a piece of pure nitrocellulose membrane (Schleicher and Schuell) over a piece of Hybond (Amersham Biosciences, Piscataway, NJ, U.S.A.). The nitrocellulose membrane traps protein complexes and the Hybond traps free nucleic acids. The radioactivity bound to each filter was quantified to determine the ratio between free and protein-bound DNA. The fraction of nucleic acid bound to the nitrocellulose was fitted to the following equation using Sigmaplot (ISI Researchsoft):
where f is fraction of nucleic acid bound, R is the maximum specific bound fraction, K is the binding constant, and B is the fraction bound to the membrane in the absence of protein. Dotblot analysis of the T. foetus IMPDH double mutants was performed in a similar manner but using 100-mer oligonucleotide (dT 100 ). 
UV cross-linking binding assay
The cross-linking assay was modified for use with IMPDH [15] . IMPDH (200 nM) from various sources was mixed with 5 -32 Pradiolabelled dT 100 . This mixture was UV-irradiated for 1 h with a hand-held UV lamp (model UVGL-25 mineral lamp), then separated by SDS/PAGE. The gels were exposed on Molecular Dynamics phosphor screens (Amersham Biosciences) that were scanned with the Molecular Dynamics Storm 840 reader.
Enzymic activity
T. foetus IMPDH was incubated in the presence and absence of saturating dT 100 (300 µM). This enzyme was added to assay solution containing 10 mM Tris/HCl, pH 8.0, 1 mM DTT, 5 mM EDTA, 50 mM KCl and sub-saturating amounts of substrate (10 µM IMP and 200 µM NAD + ). The production of NADH was followed at 340 nm using a Hitachi Instruments U-2000 spectrophotometer.
Cellular localization
Confluent human cells (K562, HeLa, PC3) were fixed with 3.7 % paraformaldehyde on to slides and permeabilized with 0.1 % Triton X-100. The primary antibody, anti-human IMPDH polyclonal rabbit antiserum, was incubated with the cells at 37
• C for 1 h. Anti-rabbit antibody conjugated to rhodamine was then incubated with the cells for 30 min at 37
• C. The cells were costained with Hoechst stain and viewed with an Olympus IX70 inverted fluorescence microscope (Melville, NY, U.S.A.).
Immunoprecipitation and digestion of nucleic acid
Nucleic acid bound to IMPDH was immunoprecipitated from K562 human cells with anti-human IMPDH antisera. Confluent human cells were cross-linked with 0.8 % formaldehyde for 20 min, quenched by 0.14 M glycine at 22
• C for 5 min, lysed at 4
• C for 30 min in RIPA buffer (10 mM Tris/HCl, pH 8, 140 mM NaCl, 1 % Triton X-100, 0.1 % SDS, 1 % deoxycholic acid, 1 mM PMSF) and sonicated. The supernatants were pre-cleared with Protein A-Sepharose and incubated with pre-immune serum, anti-IMPDH antiserum or 3.4 µg of purified recombinant human type I IMPDH followed by anti-IMPDH antiserum and precipitated with Protein A-Sepharose. The immunoprecipitate was washed extensively, eluted at 65
• C with 1 % SDS, and the crosslinks were reversed by incubating at 65
• C overnight. The resulting samples were treated with alkaline phosphatase to remove 5 -phosphates and followed by polynucleotide kinase/ [γ - 32 P]ATP to label the nucleic acid. Each sample was split into three: a control, treated with RNase One, or treated with RQ1 DNase. The nucleic acid was isolated by filter binding on a Hybond membrane and exposed as described above. Radioactivity (expressed as intensity) was compared relative to the mean of each anti-IMPDH antiserum (at least three replicate experiments were performed). The data from three independent experiments were combined and the standard errors of the mean were calculated. The significance of the difference between two groups was analysed using a two-tailed t test analysis assuming unequal variance.
ChIP (chromatin immunoprecipitation) experiments
A modified ChIP experiment was performed to demonstrate that human IMPDH binds DNA in vivo. Human cells were labelled at approx. 70 % confluency for 6 h with 1 µCi/ml 2 Ci/mmol [methyl-
3 H]thymidine. The cells were cross-linked with 0.8 % formaldehyde for 15 min, then were lysed at 4
• C for 1 h using 1 % Triton X-100, 0.1 % SDS and 1 % deoxycholic acid. The DNA was sheared using a micro-sonicator with 9 × 10 s pulses at 80 % power. The extracts were pre-cleared with Protein A-Sepharose for 1 h at 4
• C. The extracts were treated with anti-human IMPDH polyclonal antiserum for 3 h, then precipitated with Protein A-Sepharose. The immunoprecipitate was eluted with 1 % SDS and radioactivity was counted with a scintillation counter. Alternatively, the immunoprecipitate was incubated at 65
• C overnight to remove the cross-links and treated with phenol/ chloroform to remove protein. The putative nucleic-acid fraction was treated with alkaline phosphatase to remove 5 -phosphates. Alkaline phosphatase was removed by phenol/chloroform extraction, and the nucleic acid was precipitated with ethanol and NaCl. The nucleic acid was labelled with [γ -
32 P]ATP and polynucleotide kinase, and the protein was removed by phenol/chloroform extraction and ethanol precipitation. The resulting nucleic acid was treated with RNase or DNase and analysed on an 8 % denaturing acrylamide gel.
RESULTS

IMPDH binds ssDNA in a filter-binding assay
We observed that IMPDH bound to nucleic acids with nanomolar affinity in the course of aptamer selection. Typical filter-binding assays are shown in Figure 1 . IMPDHs from E. coli and T. foetus and both human isoenzymes (type I and type II) bind a random pool of 80-mer oligonucleotides, suggesting that nucleic-acid binding is a general property of IMPDH. While the E. coli and T. foetus enzymes bind approx. 75 % of the random pool, the two human isoenzymes bind only 10-20 % (approx. 10 11 sequences). This observation indicates that the human isoenzymes are more specific than the microbial enzymes. For comparison, thrombin, a protease that does not have a role in nucleic-acid metabolism but does have two positively charged exosites, binds only 0.01 % of a random oligonucleotide pool in similar aptamer selection experiments [16] . 
Nucleic acids can be UV cross-linked to IMPDH
In order to further demonstrate that IMPDH binds nucleic acid, IMPDH was incubated with 5 -32 P-labelled dT 100 and irradiated with UV light for 1 h. This treatment cross-links T. foetus IMPDH to the dT 100 as can be seen by comparing lanes 1 and 2 of Figure 2 (left-hand panel). A high-molecular-mass band appears (> 200 kDa), which consistent with the molecular mass of a tetramer of IMPDH plus oligonucleotide. The high-molecularmass band decreases in the presence of increasing concentrations of unlabelled dT 100 (Figure 2, right-hand panel) . The simplest explanation for this observation is that a single oligonucleotide cross-links all four subunits. This conclusion is substantiated in the site size experiments described below. No cross-linking was observed to the two human IMPDH isoenzymes, although it would be incorrect to conclude that these enzymes do not bind dT 100 (Figure 2, lanes 4 and 5) . Some cross-linking is observed in the E. coli IMPDH reaction, but the band is smeared and more consistent with a monomer (Figure 2, lane 7) . These variations in crosslinking patterns probably reflect differences in the structures of the nucleic-acid-binding sites among the different IMPDHs. These experiments provide further evidence that IMPDHs bind nucleic acids.
Nucleic acids do not inhibit IMPDH activity
We monitored the effects of nucleic acids on the IMPDH reaction to determine if nucleic acids bind at the active site. T. foetus IMPDH was incubated with sub-saturating concentrations of substrates (10 µM IMP compared with K m = 2 µM and 200 µM NAD + compared with K m = 150 µM) in the presence and absence of 3.5 µM dT 100 (1000 × K d , as determined below). If dT 100 binds in the dinucleotide site, as observed for many dehydrogenases, then activity should be reduced to less than 1 % under these conditions. However, no inhibition was observed; the initial rates of NADH production were identical (within experimental error) in the presence and absence of dT 100 (66 and 70 nM s −1 respectively). Thus, nucleic acids do not bind in the active site.
The IMPDH subdomain binds nucleic acids
The above observations suggest that nucleic acids bind to the 'back-end ' of the α-β barrel away from the active site and in the vicinity of the subdomain. Interestingly, the junction between the catalytic domain and the subdomain contains many positively charged residues (Figure 3 ). Therefore we determined if deletion of the subdomain impaired nucleic-acid binding. A variant of T. foetus IMPDH lacking the subdomain (Tf SD) has enzymic properties identical with the wild-type enzyme [8] . Tf SD binds to the random pool of oligonucleotides with lower affinity than wild-type (K d = 12 + − 2 nM versus 2 nM for wild-type) (Figure 1B) . UV cross-linking experiments with Tf SD also demonstrate reduced binding to dT 100 (Figure 2 , right-hand panel).
To further demonstrate that nucleic acids bind to the subdomain, we substituted conserved positively charged residues in the junction between the catalytic domain and subdomain with glutamic acid, constructing R212E/R217E and K230E/R231E in T. foetus IMPDH (Figure 3 ). These mutations do not affect enzymic activity (Table 1) , but impair nucleic-acid binding ( Figure 1C ). Both mutants bind dT 100 with an approx. 20-fold higher value of K d than wild-type IMPDH ( Figure 1C : the values of K d are 7 + − 2 nM, 70 + − 10 nM, and 120 + − 30 nM for wild-type, R212E/R217E and K230E/R231E tetramers respectively). These experiments confirm that nucleic acids bind to the back-end of the protein near the subdomain. We expressed the subdomain of human IMPDH type I in order to determine if the barrel domain is required for nucleic-acid binding. The subdomain alone binds to the random pool of oligonucleotides with an affinity of 8 + − 2 nM ( Figure 1B) . Interestingly, approx. 75 % of the pool binds to the subdomain alone, whereas only approx. 10 % bound to human IMPDH type I. Unfortunately the subdomain does not UV cross-link to dT 100 ( Figure 2 , lane 6).
The properties of nucleic-acid binding
We chose to characterize the nucleic-acid-binding properties of T. foetus IMPDH in more detail because this enzyme has a strong intrinsic protein fluorescence signal that is quenched in the presence of oligonucleotides ( Figure 4 , Table 2 ). No quenching is observed when a variety of double-stranded complexes of oligonucleotides are added to solutions of T. foetus IMPDH (results not shown). This observation indicates that IMPDH binds singlestranded, but not double-stranded, nucleic acids. No quenching is observed in the presence of heparin (a mixture of anionic polysaccharides). The failure to bind either double-stranded DNA or heparin suggests that IMPDH binds specifically to singlestranded nucleic acids, not just to polyanions. Note that the concentration units are 'per nucleotide'. Table 2 shows that longer oligonucleotides bind with higher affinity, suggesting that the binding-site size is > 60 nucleotides. IMPDH binds to RNA as well as ssDNA (Table 2) . Poly(dT), poly(U) and poly(A) bind with similar affinity, suggesting that IMPDH binds to unstructured nucleic acids. The other homo-oligonucleotides dA, dG and dC do not bind appreciably to IMPDH. In addition, no binding is observed with 20-55-mers of various sequences selected from laboratory stocks, further confirming that the binding site is > 60 bases. We also failed to observe binding to cognate RNA, which suggests that IMPDH does not regulate its own translation.
As observed in the filter-binding assay, deletion of the subdomain decreases the affinity of dT 100 and dT 60 relative to wildtype, indicating that the subdomain is involved in nucleic-acid binding. Interestingly, dT 100 and dT 60 bind to Tf SD with similar affinity. This observation suggests that deletion of the subdomain has also decreased the size of the nucleic-acid-binding site.
IMPDH binds approx. 100 bases of nucleic acid
Following the experiments of Lohman and co-workers with E. coli SSB (single-stranded DNA-binding protein) [20] , we further characterized poly(dT) binding because this homopolymer has little structure. To determine the size of the nucleic-acid-binding site, we monitored the quenching of IMPDH fluorescence by dT 100 under tight binding conditions (Figure 4) . Extrapolation of the linear portions of the graph to their intersection indicates that the site size is approx. 96 nucleotides/tetramer of IMPDH. The alternative stoichiometry of 24 nucleotides/monomer is This value is comparable with that determined in the filter-binding experiments. As expected, deletion of the subdomain reduces the site size to 60 nucleotides/tetramer (Table 2) .
Human IMPDH is located in the nucleus
We performed a series of immunofluorescence experiments to examine the localization of IMPDH. Polyclonal antibodies raised against recombinant human type II IMPDH were used as the primary antibody. These antibodies are specific for IMPDH in human cell extracts, but cannot distinguish between the two isoforms of human IMPDH (S. E. Mortimer and L. Hedstrom, unpublished results). In K562 leukaemia cells, IMPDH co-localizes with the Hoechst staining ( Figures 5A and 5B) . In PC-3 prostate cancer cells, IMPDH is found in both the cytoplasm and nucleus (Figures 5C and 5D ; note that IMPDH does not stain the nucleolus). IMPDH was also observed in both the cytoplasm and nucleus of HeLa cells (results not shown).
IMPDH is associated with nucleic acids in vivo
Our binding experiments clearly show that IMPDH binds singlestranded nucleic acid in vitro. To determine if IMPDH binds nucleic acids in vivo, K562 cells were cross-linked with formaldehyde and sonicated to fragment the DNA, as described in the Experimental section. IMPDH was immunoprecipitated with anti-human IMPDH antisera. The presence of nucleic acid was detected by treating with alkaline phosphatase followed by poly- Statistical analysis was performed using a two-tailed t test assuming unequal variance. Statistical significance is defined as P < 0.05. The asterisks denote samples that are significantly different from sample B (P = 0.02, P = 1 × 10 −5 , and P = 0.01 for samples A, C and E respectively). Samples B and D are statistically similar, as are samples A and E (P = 0.3 and P = 0.11 respectively).
nucleotide kinase/[γ -32 P]ATP and the labelled nucleic acids were isolated by filter binding (Figure 6 ). Approx. 1.5-fold more radioactivity was recovered with anti-IMPDH antiserum than with the pre-immune-serum control. The addition of recombinant human IMPDH before immunoprecipitation decreased the radioactivity to the level of the pre-immune serum. This experiment demonstrates that the excess radioactivity is associated with IMPDH. Together these results show that IMPDH binds nucleic acids in vivo. Since RNA is the predominant single-stranded nucleic acid in vivo, we determined if IMPDH-bound nucleic acid is RNA by treating the above samples with RNase. As expected, the radioactivity was degraded, indicating that most of the nucleic acid is RNA. This experiment demonstrates that IMPDH binds RNA in vivo.
A small decrease in radioactivity was also apparent when the samples were treated with DNase. Although this decrease is not statistically significant, since single-stranded DNA is much less abundant than RNA, even a small decrease could indicate that IMPDH also binds DNA in vivo. Therefore, we performed a second experiment to determine if IMPDH associates with DNA. K562 cells were treated with [ 3 H] thymidine to label DNA, and immunoprecipitated as above. Only a background level of radioactivity is observed in the immunoprecipitate in the absence of cross-linking (Table 3 , Experiment 1). Upon cross-linking, significantly more radioactivity was recovered in the presence of anti-human IMPDH antiserum. This experiment indicates that IMPDH is associated with DNA in vivo. A second experiment was performed to demonstrate further that the radioactivity was specifically associated with cellular IMPDH. As before, more radioactivity was observed in the presence of anti-human IMPDH than in the absence (Table 3 , Experiment 2; the larger amount of precipitated radioactivity in this experiment can be attributed to more efficient labelling of DNA). This radioactivity was reduced to background levels in the presence of excess recombinant human IMPDH type II, demonstrating that the radioactivity must be specifically associated with cellular IMPDH and does not fortuitously precipitate. The simplest explanation for these results is that IMPDH is also associated with DNA in vivo.
DISCUSSION
We have used three different assays to demonstrate that IMPDH binds single-stranded nucleic acids. Most importantly, the affinity of this interaction is in the low nanomolar range, comparable with the affinities observed for nucleic-acid interactions with known nucleic-acid-binding proteins [17] [18] [19] . This high affinity argues strongly against a fortuitous non-specific interaction, as does the failure to bind double-stranded DNA or heparin. The site size is 100 nucleotides, consistent with the low affinity of small oligonucleotides. This site size is larger than that of E. coli SSB (35 or 65 nucleotides per tetramer), but can be easily accommodated by the size of the IMPDH tetramer (approx. 55 kDa/monomer versus approx. 19 kDa/monomer for SSB). Lastly, IMPDH is found in the nucleus, and immunoprecipitiation experiments demonstrate that IMPDH binds RNA and DNA in vivo.
The human IMPDHs do not possess nuclear localization signals (NLS) that can be recognized by either PredictNLS [21] or PSORT II [22] . However, the prediction of protein localization is uncertain at best. Many nuclear proteins lack identifiable NLSs, and the recognition sequences have yet to be determined for approx. 50 % of the known nuclear import factors [23] , so the absence of an NLS in IMPDH is not unusual.
Several other dehydrogenases are also nucleic-acid-binding proteins, most notably glyceraldehyde 3-phosphate dehydrogenase (GAPDH). GAPDH has been independently isolated as a tRNA-, RNA-and DNA-binding protein [17, [24] [25] [26] [27] . Nucleic acids bind in the NAD site of GAPDH, which has a Rossman fold common to many other dehydrogenases [18, 28, 29] . GAPDH binds transcription regulatory elements [24] , has a uracil glycohydrolase activity [30] , is involved in nuclear/cytoplasmic transport of tRNA and oligonucleotides [17, 18] , activates ribozymes [29, 31] and cleaves RNA [32] . These activities appear to be important in transcription, DNA repair, apoptosis and viral replication [33] [34] [35] [36] and may be mediated by different GAPDH isoforms [37] .
Unlike other dehydrogenases, the NAD site of IMPDH is not involved in nucleic-acid binding, as demonstrated by the failure of nucleic acids to inhibit the IMPDH reaction. Instead, nucleic acids interact with the 'back-end ' of the enzyme and the subdomain. Nucleic-acid binding is the first function associated with the subdomain, which consists of two structural motifs similar to the regulatory domain of CBS [38] . CBS domains are also found in chloride channels, ABC transporters and protein kinases where their function is unknown [38] . CBS domain mutations have been implicated in a wide array of inherited diseases, including myotonia (chloride channel 1 [39] ) and familial hypertrophic cardiomyopathy (protein kinase Aγ 2 [40] ). Perhaps nucleic-acid binding is a general property of CBS domains, and alterations in nucleic-acid-binding activity are a common mechanism underlying these pathologies. Mutations in the subdomain of the type I isoenzyme are implicated in retinitis pigmentosa [9, 10] , as are mutations in several splicing proteins and transcription factors [41] . It seems likely that the pathological effects of IMPDH mutations result from the disruption of nucleic-acid binding, and delineation of the function of IMPDH in nucleic-acid metabolism will reveal a novel regulatory mechanism that must be crucial for photoreceptor function.
Our experiments indicate that IMPDH has a previously unsuspected role in nucleic-acid metabolism. Such additional functions can have profound therapeutic consequences, as illustrated by recent work on thymidylate synthase, which is a translational repressor in addition to its well-known role in pyrimidine biosynthesis [42, 43] . The selective toxicity of a thymidylate synthase inhibitor for Plasmodium falciparum arises from differences in translational repression rather than differences in inhibition of enzymic activity. Likewise, the nucleic-acid binding of IMPDH could have an unappreciated role in the efficacy of IMPDH-targeted chemotherapy.
Assigning physiological roles to proteins or subdomains is a difficult task, and as yet we can only speculate on the role of IMPDH in nucleic-acid metabolism. IMPDH protein concentrations increase dramatically when the guanine nucleotide pool is low, and IMPDH inhibitors cause cells to arrest at the G1/S interface [44] . In yeast, the transcription of IMPDH is linked to growth state, and decreases in post-diauxic and stationary cultures [45] . It is possible that IMPDH has an active role in these processes, maybe stabilizing ssDNA until replication can resume, or perhaps blocking transcription until guanine nucleotide levels are restored. Alternatively, since the demand for guanine nucleotides is high in translation, IMPDH could bind to mRNA and block translation until guanine nucleotide concentrations are restored. Nucleic-acid binding may simply increase the local concentration of IMPDH where the cellular demand for guanine nucleotides is high. IMPDH associates with proteins involved in transcription, translation, nuclear transport and DNA repair in genome-wide protein interaction screen, and, like GAPDH, could be involved in all of these processes [46] [47] [48] . Perhaps, like GAPDH, IMPDH has multiple isoforms to satisfy diverse functions. Indeed, the most striking differences between the two human IMPDH isoenzymes are found in the subdomain. The experiments reported here are a necessary prelude to uncovering the role of the IMPDH subdomain in vivo.
